-
National Beverage Shares Fizzing Out As Glaucus Alleges Earnings Manipulation
Wednesday, September 28, 2016 - 12:27pm | 427Glaucus Research Group proposed that National Beverage Corp. (NASDAQ: FIZZ), creator of discount sodas Faygo, Shasta, Rip It energy drinks and LaCroix sparkling water, has a history of fraud and earnings manipulation conducted through a "ludicrous corporate governance structure."...
-
Glaucus Research Profiles Tekmira Pharmaceuticals; Shares Down 2%
Monday, November 10, 2014 - 2:22pm | 227Shares of Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR) were trading lower on Monday after Glaucus Research highlighted a “Strong Sell” recommendation with a $7 to $10 price target. “Tekmira is hugely overvalued and its share price is poised to collapse,” Glaucus...
-
Glaucus Research Issues Follow-Up on Shougang Fushan; Reiterates Strong Sell (0639.HK)
Tuesday, April 24, 2012 - 4:08pm | 80Glaucus Research has released a second negative report on Shougang Fushan (0639.HK), a company traded on the Hong Kong exchange under the symbol 639 and very thinly traded on the U.S. pinksheet market under the symbol FSHYF. Glaucus Research reiterates its Strong Sell rating. Benzinga's previous...
-
Glaucus Research Initiates Shougang Fushan with Strong Sell Rating (0639.HK)
Wednesday, April 11, 2012 - 9:51pm | 188Glaucus Research has released a negative report on Shougang Fushan (0639.HK), a company traded on the Hong Kong exchange under the symbol 639 and very thinly traded on the U.S. pinksheet market under the symbol FSHYF. Glaucus Research initiates coverage today on the firm with a Strong Sell rating...
-
Benzinga Q&A: Matt Wiechert of Glaucus Research
Wednesday, April 11, 2012 - 9:26am | 941Benzinga Q&A: Matt Wiechert of Glaucus Research By now, investors are familiar with the controversies swirling around the Chinese small and mid cap universe. In the last 18 months, a significant number publicly-listed Chinese companies have found themselves the subject of scrutiny by investors...
-
China Medical Technologies—Is This Another Chinese Fraud?
Tuesday, December 6, 2011 - 12:35pm | 531Glaucus Research released an explosive report exposing alleged fraudulent transactions on the part of China Medical Technologies (NASDAQ: CMED). Compelling evidence suggests that CMED deliberately overpaid—to the tune of $20-23 million—for a company which its own Chairman was a stakeholder. The...
-
Glaucus Research Initiates China Medical Technologies at Strong Sell
Tuesday, December 6, 2011 - 7:58am | 24Glaucus Research has initiated coverage on China Medical Technologies (NASDAQ: CMED) with a Strong Sell rating.
-
Glaucus Research Raises Questions on L&L Energy
Tuesday, August 2, 2011 - 9:49am | 263Glaucus Research alleges that L&L Energy (NASDAQ: LLEN) is yet another in the ongoing list of Chinese reverse-merger frauds. Glaucus writes, "According to...SAIC filings, Dickson Lee, the CEO...is the sole owner of Zone Lin, a coal coking factory purportedly acquired by LLEN in the third...
-
Top Percentage Gainers and Losers as of 2pm 05/13/11 (ABIO, GFRE, DDS, APL, DF, VRML, DAR, SWSH, ONTY, GS, RMBS, LPHI, GGS, CA, NVDA, IMRS, MNTX, MPG, GTY)
Friday, May 13, 2011 - 2:00pm | 736Best 1) ARCA biopharma (NASDAQ: ABIO): Trading up 32.4% from yesterday's close to $2.48. Shares have traded over seven times its average daily volume in today's session. 2) Gulf Resources (NASDAQ: GFRE): Trading up 16.7% from yesterday's close to $3.15. Gulf Resources published its final response...
-
Top Percentage Gainers and Losers as of 12pm 5/13/11 (ABIO, DDS, GFRE, APL, VRML, DF, SWSH, CLSN, AERL, CA, NVDA, QTWW, IMRS, FFHL, MPG, GENE)
Friday, May 13, 2011 - 12:04pm | 489Best 1) ARCA biopharma (NASDAQ: ABIO): Trading up 16% from yesterday's close to $2.18. Shares have already traded over three times average daily volume. 2) Dillard's (NYSE: DDS): Trading up 14.3% from yesterday's close to $55.55. Dillard's reported earnings of $1.37 versus estimates of $0.91....